Loading...

Cytocom, Inc.

CBLI•NASDAQ
Healthcare
Biotechnology
$3.17
$-0.25(-7.31%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the last four quarters, Cytocom, Inc. achieved steady financial progress, growing revenue from $43645.00 in Q3 2020 to $0.00 in Q2 2021. Gross profit stayed firm with margins at N/A in Q2 2021 versus 100% in Q3 2020. Operating income totaled -$669237.00 in Q2 2021, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$669237.00. Net income dropped to -$659506.00, with EPS at -$0.04. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;